Genentech’s Faricimab Meets Primary Endpoint in 2 Global Phase III Studies, Shows Potential to Extend Treatment Frequency
Genentech announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific […]